While existing literature hints at a significant association between KRAS mutations and a heightened immunogenicity within the tumor and inflammatory microenvironment, suggesting a potential favorable response to ICI therapy, the precise impact on prognosis remains inadequately elucidated. This evidence concerns the gene KRAS and neoplasm.